title: Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus.
abstract: Toxic epidermal necrolysis (TEN) is a rare, life-threatening skin reaction for which there is currently has no standardized treatment, despite its significant mortality. Biological agents such as tumour necrosis factor (TNF)-α antagonists are emerging as a novel treatment for patients with TEN. We report a 32-year-old woman who developed TEN secondary to sulfasalazine, which was treated with infliximab. The infliximab treatment subsequently triggered erosive lichen planus (LP) involving the mouth and vulva. Clinicians should be aware that TNF-α antagonists can cause LP as a paradoxical complication of treatment.
authors.affiliation: Department of Dematology, St George's Hospital, London, UK.
authors.forename: F
authors.initials: F
authors.lastname: Worsnop
authors.forename: J
authors.initials: J
authors.lastname: Wee
authors.forename: J
authors.initials: J
authors.lastname: Natkunarajah
authors.forename: Y
authors.initials: Y
authors.lastname: Moosa
authors.forename: R
authors.initials: R
authors.lastname: Marsden
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001691:Biological Therapy / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology; D005260:Female; D006801:Humans; D000069285:Infliximab; D008010:Lichen Planus / Q000139:chemically induced*; D017676:Lichen Planus, Oral / Q000139:chemically induced; D013262:Stevens-Johnson Syndrome / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014845:Vulvar Diseases / Q000139:chemically induced*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab